Back to top
more

Cerner Corporation (CERN)

(Delayed Data from NSDQ)

$68.47 USD

68.47
2,167,881

+0.46 (0.68%)

Updated May 3, 2019 04:00 PM ET

After-Market: $68.46 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Thermo Fisher Abandons Gatan Deal in Want of European Nod

by Zacks Equity Research

Thermo Fisher (TMO) and Roper will carry on with their current long-term supply agreement.

Medtronic Delivers Favorable Outcome on Guardian Connect

by Zacks Equity Research

Medtronic's (MDT) data indicates that Guardian Connect will enable patients to better understand glucose trends and increase Time in Range.

Chemed's VITAS Business Strong, Weak Acuity Mix Shifts a Woe

by Zacks Equity Research

Chemed's (CHE) VITAS registers an expanded average daily census.

Integra LifeSciences' Organic Growth Strong on New Products

by Zacks Equity Research

Banking on product unveilings and a better sales force performance, Integra LifeSciences (IART) pins hopes on accelerated organic growth in the second half of 2019.

Tandem Releases Positive Results Of t:slim X2 Pump Studies

by Zacks Equity Research

The results of the studies are a major breakthrough for Tandem (TNDM) in the field of diabetes treatment.

Smith & Nephew (SNN) Buys Brainlab, Braces Robotic Ecosystem

by Zacks Equity Research

The transaction by Smith & Nephew (SNN), besides the business purchase, comprises certain intangible assets and the orthopaedic Brainlab salesforce.

Titan Medical (TMDI) Shows Promise on Strategic Developments

by Zacks Equity Research

Titan Medical (TMDI) is putting in a good deal of effort to strengthen its position in the multi-billion dollar computer-assisted robotic surgical technologies market.

Varian (VAR) Set to Exhibit ProBeam Proton Therapy System

by Zacks Equity Research

Varian's (VAR) ProBeam exhibition is in sync with its strategy to expand reach within the cancer care market.

DexCom and Companion Medical Collaboration to Support CGM

by Zacks Equity Research

The collaboration enables InPen users to display real-time insulin data in Dexcom's (DXCM) CLARITY Diabetes Management Software.

John Blank headshot

Bulls Focus on S&P 500 Earnings: Zacks June Strategy

by John Blank

Look back at the multiple years' sequence of annual positive share returns. Then look ahead at forward earnings fundamentals -- you gain the best perspective.

Walgreens' Weak Market Trends a Woe, Strategic Deals a Boon

by Zacks Equity Research

Walgreens Boots (WBA) is diligently trying to redress specific areas of operational weakness and enhancing its managerial skills for a better operating performance.

QIAGEN-DiaSorin Union to Enhance QuantFERON for Lyme Disease

by Zacks Equity Research

QIAGEN (QGEN) expects multi-site clinical validations for this new system during 2020 Lyme disease season.

Here's Why You Should Invest in Quest Diagnostics (DGX) Stock

by Zacks Equity Research

Quest Diagnostics (DGX) is boosting investors' optimism, courtesy of consistent positive results.

LHC Group Finalizes Joint Venture Agreement With AtlantiCare

by Zacks Equity Research

LHC Group's (LHCG) deal is in line with its current strategy of collaborating with JV partners to expand service capabilities in core markets.

Abbott (ABT) Grows on EPD Amid Rhythm Management Challenges

by Zacks Equity Research

We are optimistic about the steady growth trend in Abbott's (ABT) EPD and Medical Devices segments on an organic basis.

Here's Why You Should Invest in Omnicell (OMCL) Stock Now

by Zacks Equity Research

Omnicell (OMCL) is boosting investors' optimism, courtesy of consistent positive results.

Sweta Killa headshot

Should You Invest in the Invesco Dynamic Software ETF (PSJ)?

by Sweta Killa

Sector ETF report for PSJ

Myriad Genetics' (MYGN) POLO Study Shows Positive Results

by Zacks Equity Research

Myriad Genetics' (MYGN) collaboration with AstraZeneca garners several regulatory go-aheads for BRACAnalysis CDx test.

Is Cerner (CERN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (CERN) Outperforming Other Medical Stocks This Year?

Luminex xMAP Picked by EDP Biotech to Boost Cancer Diagnostics

by Zacks Equity Research

Management at Luminex (LMNX) expects to see robust demand for Luminex's xMAP technology in 2019.

Here's Why You Should Retain Bio-Rad (BIO) Stock For Now

by Zacks Equity Research

Bio-Rad (BIO) continues to witness high investor confidence on strength in the Life Sciences segment.

Medtronic Receives FDA Nod for SelectSite Catheter System

by Zacks Equity Research

The launch of the SelectSite catheter is in line with Medtronic's (MDT) goal to expand its cardiac care portfolio.

Masimo's Technologies to be Deployed to Boost Pediatric Care

by Zacks Equity Research

NuVision's centers are to be equipped with Masimo's (MASI) SET, Root with Radical-7, NomoLine Capnography and Patient SafetyNet technologies.

Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now

by Zacks Equity Research

IDEXX (IDXX) registers strong revenue growth on the back of CAG Diagnostics.

QIAGEN (QGEN) Launches PIK3CA Kit for Breast Cancer Patients

by Zacks Equity Research

QIAGEN's (QGEN) therascreen PIK3CA Kit is the first companion diagnostic test to have attained premarket approval from the FDA.